<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00635219</url>
  </required_header>
  <id_info>
    <org_study_id>11984A</org_study_id>
    <secondary_id>EudraCT 2007-001870-95</secondary_id>
    <nct_id>NCT00635219</nct_id>
  </id_info>
  <brief_title>Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder</brief_title>
  <official_title>A Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed-dose Study Evaluating the Efficacy and Safety of Three Dosages of [Vortioxetine] Lu AA21004, in Acute Treatment of Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and the tolerability of three fixed
      doses of Vortioxetine in order to establish the appropriate clinical effective dose range in
      the treatment of Major Depressive Disorder (MDD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in MADRS Total Score After 8 Weeks of Treatment</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Responders at Week 8 (Response Defined as a &gt;=50% Decrease in the MADRS Total Score From Baseline)</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Status Using CGI-I Score at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment in Patients With Baseline HAM-A Total Score &gt;=20</measure>
    <time_frame>Baseline and Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SDS Total Score After 8 Weeks of Treatment</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score &lt;=10)</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A Total Score After 8 Weeks of Treatment</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CGI-S Score After 8 Weeks of Treatment</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ASEX Total Score After 8 Weeks of Treatment</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The Arizona Sexual Experience Scale (ASEX) is a 5-item, patient self-rated scale that evaluates a patient's recent sexual experience. Patients are asked to assess their own experience over the last week (for example, &quot;How strong is your sex drive?&quot;, &quot;Are your orgasms satisfying?&quot;) and respond on a 6-point scale for each item. The ASEX is used to identify individuals with sexual dysfunction. Possible total score ranges from 5 to 30, with the higher score indicating more patient sexual dysfunction. A negative change indicates a lower sexual dysfunction.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">766</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vortioxetine: 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vortioxetine: 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vortioxetine: 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Duloxetine: 60 mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Active reference</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>capsules; daily; orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine (Lu AA21004)</intervention_name>
    <description>2.5 mg/day; encapsulated tablets; orally</description>
    <arm_group_label>Vortioxetine: 2.5 mg</arm_group_label>
    <other_name>Brintellix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine (Lu AA21004)</intervention_name>
    <description>5 mg/day; encapsulated tablets; orally</description>
    <arm_group_label>Vortioxetine: 5 mg</arm_group_label>
    <other_name>Brintellix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine (Lu AA21004)</intervention_name>
    <description>10 mg/day; encapsulated tablets; orally</description>
    <arm_group_label>Vortioxetine: 10 mg</arm_group_label>
    <other_name>Brintellix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>60 mg/day; encapsulated capsules; orally</description>
    <arm_group_label>Duloxetine: 60 mg</arm_group_label>
    <other_name>Cymbalta®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MDE as primary diagnosis according to DSM-IV-TR criteria (classification code 296.xx)

          -  Moderate to severe depression

          -  Current MDE duration of at least 3 months

        Exclusion Criteria:

          -  Any current psychiatric disorder other than MDD as defined in the DSM-IV TR

          -  Any substance disorder within the previous 6 months

          -  Female patients of childbearing potential who are not using effective contraception

          -  Use of any psychoactive medication 2 weeks prior to screening and during the study

        Other protocol-defined inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>France</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
  </removed_countries>
  <results_reference>
    <citation>Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012 Jul;22(7):482-91. doi: 10.1016/j.euroneuro.2011.11.008. Epub 2011 Dec 30.</citation>
    <PMID>22209361</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2008</study_first_submitted>
  <study_first_submitted_qc>March 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2008</study_first_posted>
  <results_first_submitted>October 28, 2013</results_first_submitted>
  <results_first_submitted_qc>December 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2014</results_first_posted>
  <last_update_submitted>December 23, 2013</last_update_submitted>
  <last_update_submitted_qc>December 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major depressive disorder</keyword>
  <keyword>Placebo-controlled</keyword>
  <keyword>Active reference</keyword>
  <keyword>Multicenter study</keyword>
  <keyword>Randomised study</keyword>
  <keyword>Acute treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Vortioxetine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The patients were recruited from psychiatric settings.</recruitment_details>
      <pre_assignment_details>The study consisted of a Screening Period; an 8-week Core Treatment Period; a 1-week double-blind downtaper period (Week 9); and a 4-week Safety Follow-up Period - the 4-week period after completion/withdrawal (Weeks 9 to 12).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>capsules; daily; orally</description>
        </group>
        <group group_id="P2">
          <title>Vortioxetine 2.5 mg</title>
          <description>encapsulated tablets; orally</description>
        </group>
        <group group_id="P3">
          <title>Vortioxetine 5 mg</title>
          <description>encapsulated tablets; orally</description>
        </group>
        <group group_id="P4">
          <title>Vortioxetine 10 mg</title>
          <description>encapsulated tablets; orally</description>
        </group>
        <group group_id="P5">
          <title>Duloxetine 60 mg</title>
          <description>encapsulated capsules; orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="155"/>
                <participants group_id="P3" count="157"/>
                <participants group_id="P4" count="151"/>
                <participants group_id="P5" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="130"/>
                <participants group_id="P3" count="122"/>
                <participants group_id="P4" count="117"/>
                <participants group_id="P5" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="34"/>
                <participants group_id="P5" count="42"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance With Study Product</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of Consent</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative or Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full-analysis set (FAS) - all patients in the all-patients-treated set (APTS) who had at least one valid postbaseline assessment of the primary efficacy variable</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>capsules; daily; orally</description>
        </group>
        <group group_id="B2">
          <title>Vortioxetine 2.5 mg</title>
          <description>encapsulated tablets; orally</description>
        </group>
        <group group_id="B3">
          <title>Vortioxetine 5 mg</title>
          <description>encapsulated tablets; orally</description>
        </group>
        <group group_id="B4">
          <title>Vortioxetine 10 mg</title>
          <description>encapsulated tablets; orally</description>
        </group>
        <group group_id="B5">
          <title>Duloxetine 60 mg</title>
          <description>encapsulated capsules; orally</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="148"/>
            <count group_id="B2" value="155"/>
            <count group_id="B3" value="157"/>
            <count group_id="B4" value="151"/>
            <count group_id="B5" value="155"/>
            <count group_id="B6" value="766"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.4" spread="12.5"/>
                    <measurement group_id="B2" value="46.0" spread="12.5"/>
                    <measurement group_id="B3" value="44.7" spread="13.1"/>
                    <measurement group_id="B4" value="45.2" spread="13.1"/>
                    <measurement group_id="B5" value="45.3" spread="12.0"/>
                    <measurement group_id="B6" value="44.9" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="100"/>
                    <measurement group_id="B5" value="105"/>
                    <measurement group_id="B6" value="522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="50"/>
                    <measurement group_id="B6" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MADRS</title>
          <description>The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.7" spread="4.3"/>
                    <measurement group_id="B2" value="31.6" spread="4.0"/>
                    <measurement group_id="B3" value="32.7" spread="4.8"/>
                    <measurement group_id="B4" value="31.8" spread="3.9"/>
                    <measurement group_id="B5" value="31.4" spread="4.2"/>
                    <measurement group_id="B6" value="31.9" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HAM-D-24</title>
          <description>The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.8" spread="5.1"/>
                    <measurement group_id="B2" value="29.6" spread="5.8"/>
                    <measurement group_id="B3" value="31.3" spread="5.8"/>
                    <measurement group_id="B4" value="30.4" spread="5.4"/>
                    <measurement group_id="B5" value="29.9" spread="5.8"/>
                    <measurement group_id="B6" value="30.2" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CGI-S</title>
          <description>The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.8" spread="0.7"/>
                    <measurement group_id="B2" value="4.8" spread="0.7"/>
                    <measurement group_id="B3" value="4.8" spread="0.7"/>
                    <measurement group_id="B4" value="4.7" spread="0.7"/>
                    <measurement group_id="B5" value="4.7" spread="0.7"/>
                    <measurement group_id="B6" value="4.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SDS</title>
          <description>The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.9" spread="5.8"/>
                    <measurement group_id="B2" value="19.4" spread="6.5"/>
                    <measurement group_id="B3" value="19.6" spread="6.2"/>
                    <measurement group_id="B4" value="19.6" spread="6.5"/>
                    <measurement group_id="B5" value="19.2" spread="5.9"/>
                    <measurement group_id="B6" value="19.6" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HAM-A</title>
          <description>The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.1" spread="5.6"/>
                    <measurement group_id="B2" value="22.2" spread="6.7"/>
                    <measurement group_id="B3" value="23.5" spread="6.2"/>
                    <measurement group_id="B4" value="23.4" spread="6.3"/>
                    <measurement group_id="B5" value="22.8" spread="6.4"/>
                    <measurement group_id="B6" value="23.0" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in MADRS Total Score After 8 Weeks of Treatment</title>
        <description>The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Full-analysis set (FAS) - all patients in the all-patients-treated set (APTS) who had at least one valid post-baseline assessment of the primary efficacy variable; last observation carried forward (LOCF); analysis of covariance (ANCOVA)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules; daily; orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O4">
            <title>Vortioxetine 10 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O5">
            <title>Duloxetine 60 mg</title>
            <description>encapsulated capsules; orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in MADRS Total Score After 8 Weeks of Treatment</title>
          <description>The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.</description>
          <population>Full-analysis set (FAS) - all patients in the all-patients-treated set (APTS) who had at least one valid post-baseline assessment of the primary efficacy variable; last observation carried forward (LOCF); analysis of covariance (ANCOVA)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="155"/>
                <count group_id="O3" value="155"/>
                <count group_id="O4" value="151"/>
                <count group_id="O5" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.8" spread="0.82"/>
                    <measurement group_id="O2" value="-16.2" spread="0.79"/>
                    <measurement group_id="O3" value="-16.5" spread="0.80"/>
                    <measurement group_id="O4" value="-16.3" spread="0.80"/>
                    <measurement group_id="O5" value="-16.8" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>As soon as an endpoint was non-significant at the 0.025 level of significance, the testing procedure was stopped for all subsequent endpoints.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1321</p_value>
            <p_value_desc>Since p-value &gt;0.025, hierarchically testing stopped here.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.92</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
            <estimate_desc>To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>As soon as an endpoint was non-significant at the 0.025 level of significance, the testing procedure was stopped for all subsequent endpoints.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1847</p_value>
            <p_value_desc>Since p-value &gt;0.025, hierarchically testing stopped here.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.73</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
            <estimate_desc>To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2187</p_value>
            <p_value_desc>This dose was not in the testing sequence. A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.59</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0741</p_value>
            <p_value_desc>This treatment arm was not in the testing sequence. A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.27</ci_lower_limit>
            <ci_upper_limit>0.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment</title>
        <description>The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>FAS; LOCF; ANCOVA</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules; daily; orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O4">
            <title>Vortioxetine 10 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O5">
            <title>Duloxetine 60 mg</title>
            <description>encapsulated capsules; orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment</title>
          <description>The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe.</description>
          <population>FAS; LOCF; ANCOVA</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="155"/>
                <count group_id="O3" value="155"/>
                <count group_id="O4" value="151"/>
                <count group_id="O5" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.3" spread="0.82"/>
                    <measurement group_id="O2" value="-14.4" spread="0.79"/>
                    <measurement group_id="O3" value="-15.0" spread="0.80"/>
                    <measurement group_id="O4" value="-14.9" spread="0.80"/>
                    <measurement group_id="O5" value="-15.7" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1120</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.01</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1487</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.85</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3246</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.31</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0298</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.70</ci_lower_limit>
            <ci_upper_limit>-0.24</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Responders at Week 8 (Response Defined as a &gt;=50% Decrease in the MADRS Total Score From Baseline)</title>
        <time_frame>Week 8</time_frame>
        <population>FAS; LOCF; Logistic Regression</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules; daily; orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O4">
            <title>Vortioxetine 10 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O5">
            <title>Duloxetine 60 mg</title>
            <description>encapsulated capsules; orally</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Responders at Week 8 (Response Defined as a &gt;=50% Decrease in the MADRS Total Score From Baseline)</title>
          <population>FAS; LOCF; Logistic Regression</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="155"/>
                <count group_id="O3" value="155"/>
                <count group_id="O4" value="151"/>
                <count group_id="O5" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9"/>
                    <measurement group_id="O2" value="54.2"/>
                    <measurement group_id="O3" value="56.1"/>
                    <measurement group_id="O4" value="57.6"/>
                    <measurement group_id="O5" value="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1370</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>Adjusting for Baseline</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>2.23</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0664</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>Adjusting for Baseline</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>2.43</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2023</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>Adjusting for Baseline</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>2.12</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0765</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>Adjusting for Baseline</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>2.40</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Status Using CGI-I Score at Week 8</title>
        <description>The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment.</description>
        <time_frame>Week 8</time_frame>
        <population>FAS; LOCF; ANCOVA</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules; daily; orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O4">
            <title>Vortioxetine 10 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O5">
            <title>Duloxetine 60 mg</title>
            <description>encapsulated capsules; orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Status Using CGI-I Score at Week 8</title>
          <description>The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment.</description>
          <population>FAS; LOCF; ANCOVA</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="155"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="151"/>
                <count group_id="O5" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" spread="0.10"/>
                    <measurement group_id="O2" value="2.32" spread="0.10"/>
                    <measurement group_id="O3" value="2.32" spread="0.10"/>
                    <measurement group_id="O4" value="2.35" spread="0.10"/>
                    <measurement group_id="O5" value="2.31" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1436</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2114</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1389</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1271</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment in Patients With Baseline HAM-A Total Score &gt;=20</title>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Patients With Baseline HAM-A Total Score &gt;=20: FAS; LOCF; ANCOVA</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules; daily; orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O4">
            <title>Vortioxetine 10 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O5">
            <title>Duloxetine 60 mg</title>
            <description>encapsulated capsules; orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment in Patients With Baseline HAM-A Total Score &gt;=20</title>
          <population>Patients With Baseline HAM-A Total Score &gt;=20: FAS; LOCF; ANCOVA</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.7" spread="1.10"/>
                    <measurement group_id="O2" value="-14.3" spread="1.15"/>
                    <measurement group_id="O3" value="-15.8" spread="1.09"/>
                    <measurement group_id="O4" value="-15.8" spread="1.07"/>
                    <measurement group_id="O5" value="-17.3" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4421</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.08</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4399</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.07</ci_lower_limit>
            <ci_upper_limit>1.77</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8093</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.65</ci_lower_limit>
            <ci_upper_limit>3.40</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0897</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.61</ci_lower_limit>
            <ci_upper_limit>0.41</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SDS Total Score After 8 Weeks of Treatment</title>
        <description>The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>SDS is a patient-reported outcome. The SDS Total Score is the sum of work, social life, or leisure activities, and home life or family responsibilities. FAS; LOCF; ANCOVA</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules; daily; orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O4">
            <title>Vortioxetine 10 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O5">
            <title>Duloxetine 60 mg</title>
            <description>encapsulated capsules; orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SDS Total Score After 8 Weeks of Treatment</title>
          <description>The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.</description>
          <population>SDS is a patient-reported outcome. The SDS Total Score is the sum of work, social life, or leisure activities, and home life or family responsibilities. FAS; LOCF; ANCOVA</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="115"/>
                <count group_id="O5" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.11" spread="0.72"/>
                    <measurement group_id="O2" value="-7.10" spread="0.74"/>
                    <measurement group_id="O3" value="-6.52" spread="0.73"/>
                    <measurement group_id="O4" value="-7.81" spread="0.74"/>
                    <measurement group_id="O5" value="-7.91" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6748</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.98</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.35</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0871</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.64</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3186</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.94</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0768</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.79</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score &lt;=10)</title>
        <time_frame>Week 8</time_frame>
        <population>FAS; LOCF; Logistic Regression</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules; daily; orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O4">
            <title>Vortioxetine 10 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O5">
            <title>Duloxetine 60 mg</title>
            <description>encapsulated capsules; orally</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score &lt;=10)</title>
          <population>FAS; LOCF; Logistic Regression</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="155"/>
                <count group_id="O3" value="155"/>
                <count group_id="O4" value="151"/>
                <count group_id="O5" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8"/>
                    <measurement group_id="O2" value="32.9"/>
                    <measurement group_id="O3" value="36.1"/>
                    <measurement group_id="O4" value="35.8"/>
                    <measurement group_id="O5" value="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6258</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>Adjusting for Baseline</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7178</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>Adjusting for Baseline</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8651</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>Adjusting for Baseline</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8563</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>Adjusting for Baseline</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A Total Score After 8 Weeks of Treatment</title>
        <description>The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>FAS; LOCF; ANCOVA</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules; daily; orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O4">
            <title>Vortioxetine 10 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O5">
            <title>Duloxetine 60 mg</title>
            <description>encapsulated capsules; orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A Total Score After 8 Weeks of Treatment</title>
          <description>The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.</description>
          <population>FAS; LOCF; ANCOVA</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="155"/>
                <count group_id="O4" value="151"/>
                <count group_id="O5" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.57" spread="0.63"/>
                    <measurement group_id="O2" value="-9.87" spread="0.61"/>
                    <measurement group_id="O3" value="-10.7" spread="0.61"/>
                    <measurement group_id="O4" value="-10.6" spread="0.62"/>
                    <measurement group_id="O5" value="-11.0" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1925</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.82</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2434</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.72</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7246</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.00</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0981</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.16</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CGI-S Score After 8 Weeks of Treatment</title>
        <description>The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>FAS; LOCF; ANCOVA</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules; daily; orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O4">
            <title>Vortioxetine 10 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O5">
            <title>Duloxetine 60 mg</title>
            <description>encapsulated capsules; orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CGI-S Score After 8 Weeks of Treatment</title>
          <description>The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.</description>
          <population>FAS; LOCF; ANCOVA</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="155"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="151"/>
                <count group_id="O5" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.64" spread="0.11"/>
                    <measurement group_id="O2" value="-1.83" spread="0.10"/>
                    <measurement group_id="O3" value="-1.81" spread="0.10"/>
                    <measurement group_id="O4" value="-1.83" spread="0.10"/>
                    <measurement group_id="O5" value="-1.82" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2285</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1794</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1741</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2247</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ASEX Total Score After 8 Weeks of Treatment</title>
        <description>The Arizona Sexual Experience Scale (ASEX) is a 5-item, patient self-rated scale that evaluates a patient’s recent sexual experience. Patients are asked to assess their own experience over the last week (for example, “How strong is your sex drive?”, “Are your orgasms satisfying?”) and respond on a 6-point scale for each item. The ASEX is used to identify individuals with sexual dysfunction. Possible total score ranges from 5 to 30, with the higher score indicating more patient sexual dysfunction. A negative change indicates a lower sexual dysfunction.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>FAS; LOCF; ANCOVA</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules; daily; orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O4">
            <title>Vortioxetine 10 mg</title>
            <description>encapsulated tablets; orally</description>
          </group>
          <group group_id="O5">
            <title>Duloxetine 60 mg</title>
            <description>encapsulated capsules; orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ASEX Total Score After 8 Weeks of Treatment</title>
          <description>The Arizona Sexual Experience Scale (ASEX) is a 5-item, patient self-rated scale that evaluates a patient’s recent sexual experience. Patients are asked to assess their own experience over the last week (for example, “How strong is your sex drive?”, “Are your orgasms satisfying?”) and respond on a 6-point scale for each item. The ASEX is used to identify individuals with sexual dysfunction. Possible total score ranges from 5 to 30, with the higher score indicating more patient sexual dysfunction. A negative change indicates a lower sexual dysfunction.</description>
          <population>FAS; LOCF; ANCOVA</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.65"/>
                    <measurement group_id="O2" value="-0.53" spread="0.62"/>
                    <measurement group_id="O3" value="-0.66" spread="0.64"/>
                    <measurement group_id="O4" value="-0.62" spread="0.62"/>
                    <measurement group_id="O5" value="-0.38" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7789</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.93</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8121</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.91</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8918</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.82</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9720</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.69</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious Adverse Events: 8-week double-blind treatment period and 4-week safety follow-up period Other Adverse Events: 8-week double-blind treatment period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>Vortioxetine 2.5 mg</title>
        </group>
        <group group_id="E3">
          <title>Vortioxetine 5 mg</title>
        </group>
        <group group_id="E4">
          <title>Vortioxetine 10 mg</title>
        </group>
        <group group_id="E5">
          <title>Duloxetine 60 mg</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA12_1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Serotonin syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA12_1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="62" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="93" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="52" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The main publication has to be published before any sub-publications. H. Lundbeck A/S follows the Vancouver declaration with respect to authorship.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>H. Lundbeck A/S</name_or_title>
      <organization>H. Lundbeck A/S</organization>
      <phone>+45 3630 1311</phone>
      <email>LundbeckClinicalTrials@lundbeck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

